Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Natalizumab in Relapsing-Remitting Multiple Sclerosis
NCT00027300Phase 3Completed
- Sponsor
- Biogen
- Start
- Nov 2001
- Primary completion
- Nov 2004
- Modality
- Monoclonal Antibodies
- Countries
- 8
01
Overview
Phase 3, randomised, double-blind trial in relapsing-remitting multiple sclerosis (RRMS) comparing Natalizumab Arm with Placebo Arm (2 arms). Primary endpoints: Rate of clinical relapses at 1 year and Progression of disability at 2 years. Started Nov 2001; status: completed.
02
Drugs
natalizumab
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on NCT00027300.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00027300.